BA
CLDX icon

Bellwether Advisors’s Celldex Therapeutics CLDX Stock Holding History

Bellwether Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,623
Closed -$627K – 569
2021
Q3 		$627K Buy
+11,623
New +$545K 0.21% 79

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bellwether Advisors's CLDX Position: Q4 2021 in Review

Bellwether Advisors sold out of Celldex Therapeutics (CLDX) in Q4 2021, closing a stake of 11,623 shares — an estimated $627K sold.

Bellwether Advisors first reported a position in CLDX in Q3 2021 and held it in 1 quarter. The position peaked at $627K in Q3 2021. 180 funds tracked by Wall St. Rank hold CLDX as of Q4 2021.

  • Bellwether Advisors reported no remaining Celldex Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Bellwether Advisors sold 11,623 Celldex Therapeutics shares in Q4 2021, an estimated $627K.
  • Bellwether Advisors first reported a position in Celldex Therapeutics in Q3 2021 and held it in 1 quarter.
  • Bellwether Advisors's Celldex Therapeutics position peaked at $627K in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2021.

Based on Bellwether Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.